OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
OnKure Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.25+0.15 (+7.14%)
Close on Oct 19, 2026
- Market cap
- $112.21M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.53 (−19.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $112.21M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.65
- Dividend yield
- –
- Free cash flow yield
- -42.66%
Fundamentals
- Net income
- -$58.71M
- EPS, diluted
- -$3.50
- Free cash flow
- -$47.86M
- Book value per share
- $3.45
- Diluted shares
- 50M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$62.14M
Net income
-$58.71M
EPS, diluted
-$3.50
Free cash flow
-$47.86M
Reported periodTrailing twelve months